Active substanceBetagistinBetagistin
Similar drugsTo uncover
  • Betavert®
    pills inwards 
    VEROPHARM SA     Russia
  • Betavert®
    pills inwards 
    VEROPHARM SA     Russia
  • Betagistin
    pills inwards 
  • Betagistin
    pills inwards 
    VERTEKS, AO     Russia
  • Betagistin
    pills inwards 
    VERTEKS, AO     Russia
  • Betagistin
    pills inwards 
    HEALTH OF CNT, CJSC     Russia
  • Betagistin
    pills inwards 
    OZONE, LLC     Russia
  • Betagistin
    pills inwards 
    ZIO-HEALTH, JSC     Russia
  • Betagistin
    pills inwards 
    PRANAFARM, LLC     Russia
  • Betagistin
    pills inwards 
    OZONE, LLC     Russia
  • Betagistin
    pills inwards 
  • Betagistin Canon
    pills inwards 
  • Betagistin Mediabsor
    pills inwards 
    MEDISORB, CJSC     Russia
  • Betagistin-Nanolek
    pills inwards 
    NANOLEC, LTD.     Russia
  • Betagistin-SZ
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Betaserc®
    pills inwards 
    Abbott Helskea Products BV     Netherlands
  • Betaserc®
    pills inwards 
    Abbott Helskea Products BV     Netherlands
  • Betacentrine
    pills inwards 
  • Vortran®
    pills inwards 
  • Vestibo®
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Vestibo®
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Vestap
    capsules inwards 
    OZONE, LLC     Russia
  • Vestap
    capsules inwards 
    OZONE, LLC     Russia
  • Micrometer
    dropspills inwards 
  • Tagista®
    pills inwards 
  • Dosage form: & nbsppills
    Composition:

    1 the tablet contains:

    active substance: betahistine dihydrochloride 8 mg, 16 mg, 24 mg;

    Excipients: cellulose microcrystalline 76.5 mg, 153.0 mg, 229.5 mg; lactose (milk sugar) 23.75 mg, 47.5 mg, 71.25 mg; citric acid 2.5 mg, 5 mg, 7.5 mg; silicon dioxide colloid (aerosil) 5.8 mg, 11.6 mg, 17.4 mg; talc 1.75 mg, 3.5 mg, 5.25 mg; magnesium stearate 1.2 mg, 2.4 mg, 3.6 mg; sodium lauryl sulfate 2.5 mg, 5.0 mg, 7.5 mg; starch 1500 (pregelatinized starch) 3.0 mg, 6.0 mg, 9.0 mg

    Description:

    Tablets 8 mg: white or almost white color, flat-cylindrical shape, with a bevel.

    Tablets 16 mg and 24 mg: white or almost white color, flat-cylindrical shape, with a facet and a risk.

    Pharmacotherapeutic group:Histamine drug
    ATX: & nbsp

    N.07.C.A.01   Betagistin

    Pharmacodynamics:

    Betagistin acts mainly on histamine H1- and H3receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic effects on H1receptors of the vessels of the inner ear, as well as indirectly through exposure to H3-receptors improves microcirculation and permeability of capillaries, normalizes the pressure of the endolymph in the labyrinth and cochlea. At the same time betagistin increases blood flow in the basilar artery.

    Has a pronounced central effect, being an inhibitor of H3receptors of the nuclei of the vestibular nerve. Improves conductivity in the neurons of the vestibular nuclei at the level of the brainstem.

    The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in noise in the ears, and improvement in hearing in the event of a decrease in it.

    Pharmacokinetics:

    Absorbed quickly, the connection with plasma proteins is low. The maximum concentration in the blood plasma after 3 hours. Half-life after 3-4 hours. It is almost completely excreted by the kidneys in the form of metabolite (2-pyridylacetic acid) for 24 hours.

    Indications:

    - LPrevention and prevention of vestibular vertigo of various origin;

    - syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;

    - disease or Meniere's syndrome.

    Contraindications:

    - Hypersensitivity to any of the components of the drug;

    - children under 18 years of age (due to lack of data);

    - pregnancy and lactation (due to lack of data).

    Carefully:

    Peptic ulcer of stomach or duodenum (including in anamnesis), pheochromocytoma, bronchial asthma.

    These patients should be observed regularly during the treatment period.

    Pregnancy and lactation:

    There is insufficient data to assess the effects of the drug during pregnancy and lactation. In this regard, not recommended during pregnancy. For the duration of treatment it is necessary to stop breastfeeding.

    Dosing and Administration:

    Inside, with food.

    Tablets 8 mg: 1-2 tablets 3 times a day.

    Tablets 16 mg: ½-1 tablet 3 times a day.

    Tablet 24 mg: 1 tablet 2 times a day.

    Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment. Treatment is long. Duration of drug intake is selected individually.

    Side effects:

    Gastrointestinal disorders, the emergence of reactions of hypersensitivity from the skin (rash, itching, urticaria), Quincke's edema.

    Overdose:

    Symptoms: nausea, vomiting, convulsions.

    Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
    Interaction:

    Cases of interaction or incompatibility with other drugs are unknown.

    Effect on the ability to drive transp. cf. and fur:

    Betagistin has no sedative effect and does not affect the ability to drive a car or engage in activities requiring rapidity of psychomotor reactions.

    Form release / dosage:

    Tablets, 8 mg, 16 mg and 24 mg.

    Packaging:

    For 10 or 20 tablets per contour cell packaging made of polyvinylchloride film and foil aluminum printed.

    For 20, 30 tablets in a can of polymer or a bottle of polymer.

    Each jar or bottle, or 2, 3, 6, 10 contour cell packs of 10 tablets, or 3, 5 contour cell packs of 20 tablets together with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, dark place, at a temperature not youwe 25 ° С

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-001047/08
    Date of registration:26.02.2008 / 17.02.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:NORTH STAR, CJSC NORTH STAR, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspNORTH STAR CJSC NORTH STAR CJSC Russia
    Information update date: & nbsp24.01.2017
    Illustrated instructions
      Instructions
      Up